tiprankstipranks
Trending News
More News >
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
US Market
Advertisement

Kymera Therapeutics (KYMR) Earnings Dates, Call Summary & Reports

Compare
346 Followers

Earnings Data

Report Date
Oct 30, 2025
Before Open (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
-0.74
Last Year’s EPS
-0.82
Same Quarter Last Year
Based on 18 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Aug 11, 2025|
% Change Since: 10.27%|
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials, a strong pipeline with promising collaborations, and a robust financial position. Despite a shift in focus for the IRAK4 program, the overall trajectory remains positive.
Company Guidance -
Q3 2025
During the Kymera Therapeutics Second Quarter 2025 Results Call, the company provided guidance on its strategic developments and financial outlook. The call highlighted significant progress in their STAT6 program, with positive results from the KT-621 trial in healthy volunteers surpassing target product profiles, suggesting potential as a first-in-class treatment for dermatological and respiratory diseases. The company also announced two partnerships, one with Gilead for a CDK2 degrader program with potential payments up to $750 million, and another with Sanofi, which opted into the IRAK4 program, potentially bringing $975 million in milestones. Financially, Kymera raised $288 million in a follow-on offering, increasing its cash position to $1 billion, extending its runway into the second half of 2028. The company plans to initiate several Phase III studies and further develop its early-stage pipeline.
Positive Results for KT-621
Completed the first KT-621 trial in healthy volunteers with results exceeding expectations, surpassing target product profile, and demonstrating potential as a first-in-class treatment for dermatological and respiratory diseases.
Strong Pipeline and Collaborations
Selected a follow-on STAT6 degrader with strong potency and advanced it through all required IND-enabling studies. Announced partnerships with Gilead for the CDK2 program and Sanofi for the IRAK4 program, potentially realizing significant milestones.
Extended Cash Runway
Extended cash runway into the second half of 2028 with a cash position of $1 billion, providing resources to advance multiple programs into Phase III studies.

Kymera Therapeutics (KYMR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

KYMR Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Oct 30, 2025
2025 (Q3)
-0.73 / -
-0.82
Aug 11, 2025
2025 (Q2)
-0.81 / -0.95
-0.58-63.79% (-0.37)
May 09, 2025
2025 (Q1)
-0.91 / -0.82
-0.69-18.84% (-0.13)
Feb 27, 2025
2024 (Q4)
-0.78 / -0.88
-0.25-252.00% (-0.63)
Oct 31, 2024
2024 (Q3)
-0.83 / -0.82
-0.98.89% (+0.08)
Aug 07, 2024
2024 (Q2)
-0.68 / -0.58
-0.6713.43% (+0.09)
May 02, 2024
2024 (Q1)
-0.72 / -0.69
-0.71.43% (+0.01)
Feb 22, 2024
2023 (Q4)
-0.40 / -0.25
-0.658.33% (+0.35)
Nov 02, 2023
2023 (Q3)
-0.64 / -0.90
-0.79-13.92% (-0.11)
Aug 03, 2023
2023 (Q2)
-0.64 / -0.67
-0.7814.10% (+0.11)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

KYMR Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Aug 11, 2025
$40.62$37.68-7.24%
May 09, 2025
$30.77$30.07-2.27%
Feb 27, 2025
$35.36$30.25-14.45%
Oct 31, 2024
$47.67$46.17-3.15%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Kymera Therapeutics (KYMR) report earnings?
Kymera Therapeutics (KYMR) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).
    What is Kymera Therapeutics (KYMR) earnings time?
    Kymera Therapeutics (KYMR) earnings time is at Oct 30, 2025, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is KYMR EPS forecast?
          KYMR EPS forecast for the fiscal quarter 2025 (Q3) is -0.74.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis